These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34572775)

  • 1. Current Immunotherapeutic Strategies for the Treatment of Glioblastoma.
    Dapash M; Castro B; Hou D; Lee-Chang C
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of glioblastoma immunotherapy.
    Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
    J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas.
    Nesseler JP; Schaue D; McBride WH; Lee MH; Kaprealian T; Niclou SP; Nickers P
    Adv Radiat Oncol; 2019; 4(2):268-282. PubMed ID: 31011672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 9. Navigating the Immune Challenge in Glioblastoma: Exploring Immunotherapeutic Avenues for Overcoming Immune Suppression.
    Jain P; Vashist S; Panjiyar BK
    Cureus; 2023 Sep; 15(9):e46089. PubMed ID: 37900496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
    Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
    J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.
    Niedbała M; Malarz K; Sharma G; Kramer-Marek G; Kaspera W
    Onco Targets Ther; 2022; 15():437-468. PubMed ID: 35509452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario.
    Bianconi A; Palmieri G; Aruta G; Monticelli M; Zeppa P; Tartara F; Melcarne A; Garbossa D; Cofano F
    Biomedicines; 2023 May; 11(6):. PubMed ID: 37371615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
    Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Immunotherapy for Adult Glioblastoma.
    Chokshi CR; Brakel BA; Tatari N; Savage N; Salim SK; Venugopal C; Singh SK
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.